Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC)
Begum FD, Høgdall EVS, Riisbro R, Christensen IJ, Engelholm SA, Jørgensen M, Pedersen BN, Høgdall CK. Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC). APMIS 2006;114:675–81.
The level of the soluble urokinase plasminogen activator receptor (suPAR) is elevated in tumour tissue from several types of cancer. This is the first study aiming to predict the prognosis for survival by the use of a pre-chemotherapeutic plasma suPAR value in 71 patients with recurrent epithelial ovarian cancer (REOC). For determination of suPAR, pre-chemotherapeutic blood samples from the patients with REOC were processed into plasma (EDTA) within one working day from venipuncture. The plasma suPAR level is not correlated with performance status (p=0.41), FIGO stage (p=0.09), treatment-free interval (TFI) of 12 months (p=0.26), site of recurrence (peritoneum, p=0.50 or pelvis, p=0.44), age (p=0.43), or serum CA125 (p=0.09). Univariate as well as multivariate analyses cannot demonstrate that high pre-chemotherapeutic levels of plasma suPAR (p=0.22, p=0.80) are associated with shorter survival of REOC patients. Multivariate analysis showed that only TFI of 12 months (p=0.001) and performance score status of 2 (p=0.02) were independent prognostic factors. Our study indicates that pre-chemotherapeutic measurement of plasma suPAR level in REOC patients may not be useful to identify a subgroup of patients with poor prognosis.
Document Type: Research Article
The Gynaecologic Clinic, The Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital,
Institute of Cancer Epidemiology, Department of Virus, Hormones and Cancer, Danish Cancer Society,
The Finsen Laboratory, Rigshospitalet, Copenhagen University Hospital,
Department of Surgical Gastroenterology, Hvidovre Hospital, Copenhagen University Hospital,
Department of Oncology, The Finsen Center, Rigshospitalet, Copenhagen University Hospital, and
Department of Clinical Biochemistry, Statens Serum Institute, Copenhagen, Denmark
Publication date: October 1, 2006